Research Analysts Issue Forecasts for ZVRA FY2028 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright cut their FY2028 EPS estimates for shares of Zevra Therapeutics in a report released on Wednesday, November 20th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of $2.51 for the year, down from their previous forecast of $2.71. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the firm posted ($0.40) earnings per share.

A number of other research firms also recently weighed in on ZVRA. Maxim Group boosted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Roth Mkm boosted their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Canaccord Genuity Group decreased their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, JMP Securities started coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Trading Up 1.8 %

Shares of NASDAQ ZVRA opened at $9.13 on Thursday. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.30. The company has a market cap of $487.36 million, a PE ratio of -4.69 and a beta of 1.93. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average of $8.12 and a two-hundred day moving average of $6.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its position in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Zevra Therapeutics in the first quarter worth $64,000. The Manufacturers Life Insurance Company lifted its position in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC bought a new stake in shares of Zevra Therapeutics in the third quarter worth $92,000. Finally, XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics in the third quarter worth $94,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.